mln-1202
mAbexperimental
Clinical trial activity
7 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2005 (NCT01199640)
Timeline
Indications
Mechanism of action
- C-C chemokine receptor type 2ANTAGONIST
CCR2 antagonist
- C-C chemokine receptor type 2INHIBITOR
CCR2 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2109339 ↗
Also known as
- mln1202
- mln1202
- mln-1202
- tak-202
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02723006 | Phase 1 | Jul 5, 2016 | Millennium Pharmaceuticals |
| NCT02388971 | Phase 2 | Apr 1, 2016 | Takeda |
| NCT02410499 | Phase 2 | Apr 1, 2016 | Takeda |
| NCT02426021 | Phase 1 | Apr 1, 2015 | Takeda |
| NCT01015560 | Phase 2 | Mar 1, 2010 | National Cancer Institute (NCI), Southwest Oncology Group, University of Michigan |
| NCT00715169 | Phase 2 | Aug 1, 2005 | Millennium Pharmaceuticals |
| NCT01199640 | Phase 2 | May 1, 2005 | Millennium Pharmaceuticals |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Millennium Pharmaceuticals | For profit | 3 | 3 | 2 | 2005 |
| Takeda | For profit | 3 | 3 | 2 | 2015 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2010 |
| Southwest Oncology Group | Academic/Hospital | 1 | 1 | 1 | 2010 |
| University of Michigan | Academic/Hospital | 1 | 0 | 1 | 2010 |
5 organizations
Page 1 / 1